Activity of doxycycline against respiratory pathogens.
149 patients were admitted from the Brussels area to the multi-centre Pan European trial of doxycycline in respiratory tract infections. Of these, 40 satisfied the strict criteria for detailed bacteriological study with positive culture of a known pathogen before treatment and bacteriological follow-up after treatment. The pathogens were beta-haemolytic streptococcus, group A (29 cases), pneumococcus (6 cases) and Haemophilus influenzae (6 cases); in one case, the pneumococcus and H. influenzae were present together. The results of doxycycline therapy were excellent, this included both its in vivo and in vitro activity; only one strain of pneumococcus proved resistant.
D001991:Bronchitis / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004318:Doxycycline / Q000627:therapeutic use*; D006192:Haemophilus Infections / Q000188:drug therapy; D006193:Haemophilus influenzae / Q000302:isolation & purification; D006801:Humans; D010612:Pharyngitis / Q000188:drug therapy; D011008:Pneumococcal Infections / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D013183:Sputum / Q000382:microbiology; D013290:Streptococcal Infections / Q000188:drug therapy; D013296:Streptococcus pneumoniae / Q000302:isolation & purification; D013297:Streptococcus pyogenes / Q000302:isolation & purification; D014069:Tonsillitis / Q000188:drug therapy
D004318:Doxycycline